Avadel Pharmaceuticals (AVDL) Q3 2024 earnings summary

Executive summary

• Net product revenue reached $50 million in Q3 2024, up from $7 million in Q3 2023, driven by LUMRYZ sales and consistent patient growth, with 2,300 active patients and 700 new starts.

• FDA approved LUMRYZ for pediatric narcolepsy (ages 7+), granting Orphan Drug Exclusivity through October 2031 and expanding the eligible treatment population.

• Operating loss narrowed to $0.3 million in Q3 2024 from $35.1 million in Q3 2023, with net loss per share improving to $0.03.

• Initiated Phase 3 trial (REVITALYZ) for LUMRYZ in idiopathic hypersomnia and advanced preclinical work on new formulations.

• Secured favorable court rulings affirming FDA approval and clinical superiority for LUMRYZ, allowing continued sales despite ongoing patent litigation.

Financial highlights

• Q3 2024 net revenue was $50 million; gross profit was $43.9 million (gross margin ~88%).

• GAAP operating expenses were $44.2 million, including $6.4 million in non-cash charges; cash, cash equivalents, and marketable securities totaled $65.8 million at quarter end.

• Adjusted EBITDA was positive at $6.1 million; operating loss on a GAAP basis was $327,000.

• Net cash used in operations was $54.8 million for the nine months ended September 30, 2024, a significant improvement year-over-year.

• Gross margin (excluding one-time royalty adjustment) expected to remain above 90%.

Outlook and guidance

• Management expects continued investment in LUMRYZ commercialization and clinical development, with sufficient liquidity for at least the next twelve months.

• Recurring quarterly cash operating expenses in Q4 expected to be $40–$45 million, with non-cash expenses of $6–$7 million.

• Anticipate positive cash flow in Q4, but expect seasonal impacts from fewer provider visits and higher gross-to-net deductions.

• Ongoing expansion into pediatric narcolepsy and idiopathic hypersomnia populations is anticipated to drive future growth.

• Project continued strong payer coverage and increased Medicare lives in 2025.